|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis显示文摘AIM:To determine if subclinical abnormal glucose tolerance(SAGT)has influence on survival of non-diabetic patients with liver cirrhosis.METHODS:In total,100 patients with compensatedliver cirrhosis and normal fasting plasma glucose were included.Fasting plasma insulin(FPI)levels were measured,and oral glucose tolerance test(OGTT)was performed.According to OGTT results two groups of patients were formed:those with normal glucose tolerance(NGT)and those with SAGT.Patients were followed every three months.The mean follow-up was932 d(range of 180-1925).Survival was analyzed by the Kaplan-Meyer method,and predictive factors of death were analyzed using the Cox proportional hazard regression model.RESULTS:Of the included patients,30 showed NGT and70 SAGT.Groups were significantly different only in age,INR,FPI and HOMA2-IR.Patients with SAGT showed lower 5-year cumulated survival than NGT patients(31.7%vs 71.6%,P=0.02).Differences in survival were significant only after 3 years of follow-up.SAGT,Child-Pugh B,and high Child-Pugh and Model for EndStage Liver Disease(MELD)scores were independent predictors of death.The causes of death in 90.3%of cases were due to complications related to liver disease.CONCLUSION:SAGT was associated with lower survival.SAGT,Child-Pugh B,and high Child-Pugh and MELD scores were independent negative predictors of survival. | Diego García-Compeán Joel Omar Jáquez-Quintana Fernando Javier Lavalle-González José Alberto González-González Linda Elsa Mu?oz-Espinosa Jesús Zacarías Villarreal-PérezEndocrinology Service and Department of Internal Medicine University Hospital 'Dr. José E. González' and Medical School Universidad Autónoma de Nuevo León Monterrey 64320 México Héctor J Maldonado-Garza | 2014 | World Journal of Gastroenterology2014，20，22： | 12 |
| 2 | Transcatheter aortic valve implantation in very elderly patients: immediate results and medium term follow-up显示文摘ObjectiveTo 评估立即的 transcatheter 在有严重、征兆的大动脉的狭窄的很老的病人的大动脉的阀门培植(TAVI ) 结果和中期的后续(作为).MethodsThis multicenter,观察、未来的学习在三所医院里被执行。我们包括了连续很老(>85 年) 病人与作为严重由 TAVI 对待。主要端点是在包括的二 years.ResultsThe 研究从任何原因评估死亡率有一个平均数的 160 个连续病人 87 ± 变老;2.1 年(从 85 ~ 94 年的范围) 和 18.8%± 的吝啬的逻辑 EuroSCORE;11.2% 与 57 (35.6%) 病人得分 ≥20% 。程序的成功率是 97.5% ,与 25 (15.6%) 与主要流血经历尖锐复杂并发症的病人(最经常) 。全球死亡率在住院期间是 8.8%(n = 14 ) 并且 30 天的死亡率是 10%(n = 16 ) 。中部在时期上面列在后面是 252.24 ±232.17 天。在后续时期期间, 28 (17.5%) 病人们死了(他们中的 17 个由于心脏的原因) 。估计的二年全面、心脏的幸存率使用 Kaplan-Meier 方法分别地是 71% 和 86.4% 。比例的危险回归给看了的考克斯可变 EuroSCORE ≥20 是与全面 mortality.ConclusionsTAVI 联系的唯一的变量在很老的病人的一张选择人口安全、有效。我们的调查结果支持在病人的这个复杂的组的这个新过程的采纳。 | Isaac Pascual Antonio J Mu oz-García Diego López-Otero Pablo Avanzas Manuel F Jimenez-Navarro Belén Cid-Alvarez Raquel del Valle Juan H Alonso-Briales Raimundo Ocaranza-Sanchez José M Hemández Ramiro Trillo-Nouche César Morís | 2015 | Journal of Geriatric Cardiology2015，12，4： | 1 |
| 3 | Tai Chi/Yoga effects on anxiety, heartrate,EEG and math computations显示文摘 | Field T Diego M Reif M H | 2010 | Complement Ther Clin Pract2010，16，4： | 1 |
| 4 | Accurate (PρT) data for methane from (300 to 450) K up to 180 MPa显示文摘 | Diego E C Ivan D M Kenneth R H | 2010 | Chemical Engineer Data2010，55，： | 1 |
| 5 | The fuzzy Kalman filter: State estimation using possibilistic techniques显示文摘 | Fernando M Agustin J Basil M H Diego R L Ramon G | 2006 | Fuzzy Sets and Systems2006，157，16： | 1 |
| 6 | Should Un- explained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms? 显示文摘 | Jihyung H Diego N William M | 2015 | Clinical Practice & Epidemiology in Mental Health2015，11，： | 1 |
| 7 | Prenatal program- ming of adult hypertension in the rat显示文摘 | V Matti V Diego H A Jennifer M | 2001 | Kidney Interna- tional2001，59，1： | 1 |
| 8 | The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women显示文摘 | PEDRO M MAGDALENA H DIEGO F | 2005 | Osteoporosis International2005，16，11： | 1 |
| 9 | Automatic recognition of quarantine citrus diseases显示文摘 | GEORGINA S DIEGO H M SERGIO G | 2013 | Expert Systems with Applications2013，40，9： | 1 |
| 10 | Mobilization of heavy metals by newer therapeutically useful chelating agents显示文摘 | Aposhian H V Maiorino R M Diego G R | 1995 | Toxicology1995，，97： | 1 |
| 11 | Agroinjection of tomato fruits:A tool for rapid functional analysis of transgenes directly in fruit显示文摘 | Diego O Sophie M Willemien H | 2006 | Plant Physiology2006，140，： | 1 |
| 12 | Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3显示文摘AIM: To evaluate pre-treatment factors associated with sustained virological response(SVR) in patients with hepatitis C virus(HCV) genotype 3 treated with peginterferon and ribavirin(RBV). METHODS: We retrospectively analyzed treatment naive, mono-infected HCV genotype 3 patients treated with peginterferon and RBV. Exclusion criteria included presence of other liver disease, alcohol consumption and African American or Asian ethnicity. The variables collected and compared between patients who achieved an SVR and patients who did not were as follows: gender, age, fibrosis stage, diabetes, body mass index,steatosis, INFL3 polymorphism, pre-treatment HCVRNA, type of peginterferon, RBV dose and adherence. RESULTS: A total of 107 patients treated between June, 2004 and March, 2013 were included. Mean treatment duration was 25.1(± 1.8) wk. Overall, 58%(62/107) of the patients achieved an SVR and 42%(45/107) did not. In the multivariate logistic regression analysis, pre-treatment HCV-RNA ≥ 600000 UI/m L(OR = 0.375, 95%CI: 0.153-0.919, P = 0.032) and advanced fibrosis(OR = 0.278, 95%CI: 0.113-0.684,P = 0.005) were significantly associated with low SVR rates. In patients with pre-treatment HCV-RNA ≥600000 UI/m L and advanced fibrosis, the probability of achieving an SVR was 29%(95%CI: 13.1-45.2).In patients with pre-treatment HCV-RNA < 600000UI/m L and mild to moderate fibrosis, the probability of achieving an SVR was 81%(95%CI: 68.8-93.4).CONCLUSION: In patients with HCV genotype 3infections the presence of advance fibrosis and high pre-treatment viral load might be associated with poor response to peginterferon plus RBV. These patients could benefit the most from new direct antiviral agentsbased regimes. | Sebastian Marciano Silvia M Borzi Melisa Dirchwolf Ezequiel Ridruejo Manuel Mendizabal Fernando Bessone Maria E Sirotinsky Diego H Giunta Julieta Trinks Pablo A Olivera Omar A Galdame Marcelo O Silva Hugo A Fainboim Adrian C Gadano | 2015 | World Journal of Hepatology2015，7，4： | 1 |
| 13 | Analysis of qPCR reference gene stability determination methods and a practical approach for efficiency calculation on a turbot (Scophthalmus maximus) gonad dataset显示文摘 | Diego R Jorge H U Rosa M C | 2014 | BMC Genomics2014，15，： | 1 |
| 14 | Post-acute pancreatitis diabetes:A complication waiting for more recognition and understanding显示文摘Post-acute pancreatitis diabetes(PAPD)is the second most common type of diabetes below type 2 diabetes mellitus.Due to the boom in research on this entity carried out during the last decade,its recognition has increased.However,much of the medical community still does not recognize it as a medium and long-term complication of acute pancreatitis(AP).Recent prospective cohort studies show that its incidence is about 23%globally and 34.5%in patients with severe AP.With the overall increase in the incidence of AP this complication will be certainly seen more frequently.Due to its high morbidity,mortality and difficult control,early detection and treatment are essential.However,its risk factors and pathophysiological mechanisms are not clearly defined.Its diagnosis should be made excluding pre-existing diabetes and applying the criteria of the American Diabetes Association after 90 d of resolution of one or more AP episodes.This review will show the evidence published so far on the incidence and prevalence,risk factors,possible pathophysiological mechanisms,clinical outcomes,clinical characteristics and preventive and corrective management of PAPD.Some important gaps needing to be clarified in forthcoming studies will also be discussed. | Diego García-Compeán Alan R Jiménez-Rodríguez Juan M Muñoz-Ayala José A González-González Héctor J Maldonado-Garza Jesús Z Villarreal-Pérez | 2023 | World Journal of Gastroenterology2023，29，28： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员